# Impact of the Cardio-Meds Mobile App on Heart Failure Knowledge and Medication Adherence: Pilot Randomized Controlled Trial

## TL;DR

A mobile app called Cardio-Meds improved heart failure knowledge in patients over 30 days but did not affect medication adherence.

## Contribution

The study introduces Cardio-Meds, a mobile app for heart failure self-management, and evaluates its impact on knowledge and adherence in a pilot trial.

## Key findings

- The Cardio-Meds app significantly improved heart failure knowledge scores after 30 days.
- No significant change in medication adherence was observed between the app group and the control group.
- The app was highly usable and acceptable, with most users willing to continue using it.

## Abstract

Heart failure (HF) is a prevalent chronic condition for which optimal management depends not only on guideline-directed medical therapy but also on patients’ understanding of their disease, recognition of warning signs, and sustained medication adherence, which remains challenging in routine care. Mobile health interventions may support therapeutic education and self-management; however, many available apps lack validated content and local relevance. Cardio-Meds is a mobile app developed at Geneva University Hospitals to support HF self-management through structured educational content, interactive quizzes, medication lists with reminders, and tools for monitoring weight and vital signs.

This study aims to evaluate the impact of a 30-day Cardio-Meds intervention on HF knowledge and medication adherence in patients with HF with reduced or mildly reduced ejection fraction.

We conducted a single-center, pilot randomized controlled trial in patients followed at the outpatient HF clinic or enrolled in cardiac rehabilitation at Geneva University Hospitals in 2024. Eligible participants had HF with a left ventricular ejection fraction less than 50%, were receiving HF-specific pharmacotherapy, speak French, and owned a smartphone. Participants were recruited by phone and randomized to Cardio-Meds use for 30 days, a self-guided intervention with a single standardized technical support call. Outcomes were self-assessed using standardized questionnaires: HF knowledge and self-management using the Dutch Heart Failure Knowledge Scale (DHFKS; score range 0‐15); medication adherence using the Basel Assessment of Adherence to Immunosuppressive Medication Scale, covering initiation, implementation, and persistence; and usability in the intervention group using the System Usability Scale (score range 0‐100). Between-group differences in DHFKS scores were analyzed using analysis of covariance adjusted for baseline values.

A total of 49 participants were included (25 intervention, 24 control); 78% (n=38) were male, and the mean age was 62 (SD 11.4) years. In the intervention group, median app usage was 123 (IQR 74‐273) minutes, with a median of 43 (IQR 19‐85) logins. Mean baseline DHFKS scores were similar between groups (intervention 11.1, SD 2.4 vs control 10.5, SD 2.9). At 30 days, mean scores increased significantly in the intervention group (12.4, SD 2.4; mean change +1.3; P<.001) and remained stable in the control group (10.4, SD 3; mean change –0.1; P=.82), with a significant adjusted between-group difference of +1.3 points (P<.001). No significant between-group differences were observed for medication adherence. Usability was high, with a mean score of 84.3 (SD 15), and 64% (16/25) of intervention participants reported that they would continue using the app.

In a stable ambulatory HF population, the Cardio-Meds intervention demonstrated short-term improvement in HF knowledge, while no effect was observed on medication adherence within the 30-day follow-up period. The app showed high usability and acceptability. Larger multicenter studies with longer follow-up are needed to assess clinical impact.